3.15 USD
↗ 0.10 (3.28%)AT CLOSE (11:59 AM EDT)
Black Diamond Therapeutics, Inc. Common Stock
BDTXNASDAQ • USD
3.17
↗ 0.02 (0.60%)
POST MARKET (AS OF 07:53 PM EDT)
Post Market
AS OF 07:53 PM EDT
3.17
↗ 0.02 (0.60%)
Market: CLOSED
Open?$3.06
High?$3.20
Low?$2.96
Prev. Close?$3.05
Volume?1.1M
Avg. Volume?678.7K
VWAP?$3.11
Rel. Volume?1.61x
Bid / Ask
Bid?$2.73 × 100
Ask?$3.63 × 100
Spread?$0.90
Midpoint?$3.18
Valuation & Ratios
Market Cap?174.7M
Shares Out?57.3M
Float?41.5M
Float %?72.8%
P/E Ratio?7.81
P/B Ratio?1.56
EPS?$0.39
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?8.42Strong
Quick Ratio?8.42Strong
Cash Ratio?1.33Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score100/100
P/E?7.8CHEAP▾
P/B?1.56CHEAP▾
P/S?2.50CHEAP▾
P/FCF?N/A▾
EV/EBITDA?7.6CHEAP▾
EV/Sales?2.20CHEAP▾
Returns & Efficiency
ROE?19.9%STRONG▾
ROA?15.6%STRONG▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$153.7M
News
Profile
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Employees
21
Market Cap
174.7M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2020-01-30
Address
245 FIRST STREET, 18TH FLOOR
CAMBRIDGE, MA 02142
Phone: 617-417-5868
CAMBRIDGE, MA 02142
Phone: 617-417-5868